GoKawiilCAR T Pioneer Renier Brentjens Develops Next-Gen Cell Therapies for Solid Tumors
Renier Brentjens, one of the early researchers behind CAR T cell therapy, is now developing a new generation of engineered 'living drug' treatments. His current work aims to extend the success these therapies have had against blood cancers to solid tumors, which have proven far harder to treat with cell-based approaches.
GoKawiil's interpretation of the reporting above, not reported fact.
CAR T therapies have already reshaped treatment for certain blood cancers by using genetically modified immune cells to target tumors, but solid tumors present tougher biological barriers such as physical tumor structure and immune suppression. Success in this next phase could significantly widen the number of cancer patients who benefit from living-cell therapies, though the technical challenges suggest such breakthroughs may take considerable time to materialize.
- Renier Brentjens helped pioneer CAR T cell therapy for blood cancers.
- He is now working on next-generation cell therapies aimed at solid tumors.
- Solid tumors pose distinct biological challenges compared to blood cancers, making this an ambitious research frontier.
Source: gizmodo.com, 2026-09-26
Published there as: “Living Drugs Transformed Blood Cancer Treatment—and That’s Just the Beginning”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.